Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Oct 2002
Randomized Controlled Trial Multicenter Study Clinical TrialDose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
To evaluate the safety, pharmacokinetics and clinical efficacy of the intercellular adhesion molecule-1 antisense phosphorothioate oligonucleotide alicaforsen (ISIS 2302) at 250-350 mg in Crohn's disease. ⋯ Alicaforsen (ISIS 2302), at fixed doses of 300 and 350 mg, achieved the desired drug exposure and may be an effective therapy for Crohn's disease. Infusion-related reactions were observed less frequently in patients on corticosteroids, and with decreasing frequency with continued treatment.
-
Aliment. Pharmacol. Ther. · Sep 2002
Randomized Controlled Trial Clinical TrialEffects of enteric-coated, low-dose aspirin on parameters of platelet function.
Aspirin is widely used as an anti-thrombotic drug; however, it has been suggested that enteric-coated formulations of aspirin may be less bioavailable and less effective as anti-thrombotic agents. ⋯ The anti-platelet effects of multiple, daily, low-dose aspirin (as assessed by inhibition of serum thromboxane B2 and platelet aggregation) are not adversely affected by enteric coating.
-
Aliment. Pharmacol. Ther. · Aug 2002
The effect of regular medication on the outcome of paracetamol poisoning.
Patients admitted with paracetamol overdose frequently receive one or more types of regular medication that may affect the outcome of the paracetamol intoxication. ⋯ Regular medication with psychotropic medication, analgesics, oral contraceptives, beta-agonists or anticonvulsants was frequent in patients admitted with paracetamol poisoning. Medication with opioid analgesics was associated with a significantly increased incidence of hepatic dysfunction, whereas the other medications did not appear to affect the outcome of the paracetamol intoxication.
-
Aliment. Pharmacol. Ther. · Jul 2002
ReviewReview article: treatment of mild and severe cases of GERD.
GERD prevalence continues to rise in contrast to peptic ulcer disease. The spectrum contains reflux esophagitis and so-called 'endoscopy-negative GERD' or 'non-erosive GERD' (NERD) or S-GERD and patients with 'normal' overall 24-h esophageal acidification but with a high 'symptom-index'. The majority of reflux patients will not need endoscopy initially. ⋯ Once a dose of the acid suppressant that relieves symptoms is found, this dose should be maintained for a period of 3 months. After this time, an attempt should be made to reduce the dose. A plan should be formulated for long-term treatment.
-
Aliment. Pharmacol. Ther. · May 2002
Comparative StudyComparison of the main oesophageal pathophysiological characteristics between short- and long-segment Barrett's oesophagus.
To assess the oesophageal manometric characteristics and 24-h pH profiles of patients with both short-segment and long-segment Barrett's oesophagus and compare them with those of patients with reflux oesophagitis and controls. ⋯ Long-segment Barrett's oesophagus is characterized by a greater impairment of peristaltic wave amplitude and a higher oesophageal acid exposure than is short-segment Barrett's oesophagus. However, both forms are linked to increased acid reflux.